HB 2292 expands insurance coverage and removes utilization-management barriers for HIV prevention and treatment in Oregon. For health benefit plans that already cover counseling, prevention services, or screening for sexually transmitted infections, the bill requires coverage of FDA-approved HIV prevention drugs, the services needed to start or continue those drugs (including office visits, testing, vaccinations, and monitoring), and FDA-approved HIV treatment drugs. The bill also specifies that the prevention-related coverage must be provided without cost-sharing, coinsurance, or deductibles.
The bill further limits prior authorization and step therapy for HIV-related medications. Insurers may not require prior authorization for post-exposure prophylaxis, pre-exposure prophylaxis, or HIV/AIDS treatment drugs, and may not restrict reimbursement for those medications to in-network pharmacies or pharmacists, with an exception for health maintenance organizations. In the Medicaid context, the Oregon Health Authority and coordinated care organizations are barred from requiring prior authorization or step therapy for FDA-approved HIV treatment or prevention drugs when the prescribing provider determines the drug is medically necessary, while still allowing drug utilization review for patient safety and federal compliance.
HB 2292 amends Oregon insurance law, including ORS 743B.001 and 743B.425, and adds new provisions to the Insurance Code and Medicaid statutes. It applies to health benefit plans offered, renewed, or extended on or after the effective date. The bill also increases expenditure limits for the Public Employees’ Benefit Board and the Oregon Educators Benefit Board to account for the expected cost of the new coverage requirements.
The overall sentiment around the bill appears strongly supportive and noncontroversial. It passed the House committee, House floor, and Senate floor unanimously, with no recorded nays at any stage shown in the voting history. That pattern suggests broad bipartisan agreement on expanding access to HIV prevention and treatment and reducing administrative barriers to care.
The main policy issue reflected in the bill is the balance between access and insurer utilization controls. The bill’s supporters appear to favor removing prior authorization, step therapy, and cost-sharing barriers to improve timely access to PrEP, PEP, and HIV treatment, while the remaining safeguards preserve insurer and Medicaid review authority for safety and medical necessity. No specific opposition is reflected in the available transcripts or votes, and the only notable carveout is the exception for HMOs in the network-pharmacy restriction.
The bill changes Oregon’s insurance and Medicaid rules by mandating coverage for FDA-approved HIV prevention and treatment drugs and related services, prohibiting cost-sharing for certain prevention coverage, and restricting prior authorization and step therapy for HIV-related medications. It also updates statutory definitions and utilization-review provisions in ORS chapter 743B, and it directs the Oregon Health Authority and coordinated care organizations not to impose prior authorization or step therapy for medically necessary, FDA-approved HIV drugs. In addition, it raises spending authority for PEBB and OEBB to implement the new benefit requirements, affecting public employee and educator health plans as well as private health benefit plans and Medicaid enrollees.
The bill’s reception was uniformly positive in the available record. It advanced out of committee with unanimous votes, then passed both chambers without any recorded opposition. The vote pattern indicates broad support for improving access to HIV prevention and treatment and for reducing insurance barriers that can delay care.
No major contention is evident in the provided materials. The only potentially sensitive policy questions are whether insurers and Medicaid managed care organizations should retain prior authorization, step therapy, and network restrictions for HIV drugs, and how much the expanded coverage will cost public and private plans. The bill resolves those questions largely in favor of access, while preserving limited utilization review for safety and federal Medicaid compliance and preserving an HMO exception for one network-related provision.